Although the current research on the AHR binding pathway and serous ovarian tumors is still limited, it can be roughly understood that the AHR binding pathway influences the formation and occurrence of serous ovarian malignancy through the deep deletion and amplification of AHR transcription factors [95,96,104,105]. This evidence concerns the gene AHR and ovarian serous tumor.